Provided by Tiger Fintech (Singapore) Pte. Ltd.

MiNK Therapeutics, Inc.

20.31
-2.9400-12.65%
Post-market: 20.490.1800+0.89%19:59 EDT
Volume:682.98K
Turnover:14.77M
Market Cap:80.95M
PE:-8.13
High:24.00
Open:23.21
Low:20.14
Close:23.25
Loading ...

Mink Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
18 Mar

MiNK Therapeutics Q4 2024 GAAP EPS $(0.62) Misses $(0.50) Estimate

Benzinga
·
18 Mar

Press Release: MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Dow Jones
·
18 Mar

Mink Therapeutics Inc expected to post a loss of 50 cents a share - Earnings Preview

Reuters
·
14 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
14 Mar

Mink Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

THOMSON REUTERS
·
04 Mar

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

GlobeNewswire
·
04 Mar

Health Check:  Half-price sale as brokers ring the bell on Neuren shares

Stockheads
·
04 Mar

Promising Early Results from MiNK Therapeutics’ Phase 2 Study of agenT-797 in Refractory GEC Justify Buy Rating

TIPRANKS
·
25 Feb

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

GlobeNewswire
·
24 Feb

Mink Therapeutics Regains Full Compliance With Nasdaq Listing Requirements

THOMSON REUTERS
·
20 Feb

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

GlobeNewswire
·
13 Feb

Mink Therapeutics Inc trading halted, news pending

TIPRANKS
·
28 Jan

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

GlobeNewswire
·
24 Jan

Mink Therapeutics Inc - to Effect 1-for-10 Reverse Stock Split

THOMSON REUTERS
·
22 Jan